Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose 5% provides a source of calories and hydration; sodium chloride 0.45% provides electrolytes and maintains osmotic balance. Dextrose is metabolized to carbon dioxide and water, yielding energy. Sodium chloride dissociates to maintain extracellular fluid volume and osmolality.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Fluid and electrolyte replacement,Treatment of dehydration,Maintenance of hydration and caloric supply in patients unable to take oral fluids,Diluent for compatible medications
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
Intravenous administration; typical adult dose is 1000-2000 m L over 24 hours, rate adjusted based on patient's fluid and electrolyte status. Maximum infusion rate is 1000 m L per hour.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Dextrose: not applicable as it is rapidly metabolized; the half-life of infused glucose is approximately 1.5-2 hours in healthy individuals, but prolonged in conditions like diabetes. Sodium: biological half-life is 10-20 hours, depending on fluid balance and renal function.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Dextrose undergoes glycolysis and subsequent oxidation via the citric acid cycle. Sodium chloride is not metabolized; it is excreted unchanged by the kidneys.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Dextrose is metabolized to carbon dioxide and water, with negligible renal excretion of intact dextrose under normal conditions. Sodium and chloride are primarily excreted renally; sodium excretion is regulated by glomerular filtration and tubular reabsorption, while chloride follows sodium. In patients with normal renal function, >90% of infused sodium and chloride are excreted in urine within 24-48 hours.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Dextrose: negligible binding to plasma proteins. Sodium: minimal binding (approx. 0-10%) to albumin and other proteins. Chloride: not significantly protein bound.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
Dextrose: distributes into total body water, approximately 0.55-0.65 L/kg (based on 60% of body weight as water in adults). Sodium: distributes into extracellular fluid, approximately 0.20-0.25 L/kg. Chloride: similar to sodium, extracellular fluid, approximately 0.20 L/kg.
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Intravenous: 100% for all components.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
For GFR < 10 m L/min: reduce to 50% of standard dose or avoid due to risk of volume overload and hypernatremia; monitor closely for signs of fluid overload and electrolyte disturbances.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
Not required: no dose adjustment needed for hepatic impairment.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Intravenous; dose based on daily maintenance fluid requirements: 0-10 kg: 100 m L/kg/day; 10-20 kg: 1000 m L + 50 m L/kg for each kg over 10; >20 kg: 1500 m L + 20 m L/kg for each kg over 20. Infusion rate adjusted to patient's clinical status.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Use with caution: lower initial doses and slower infusion rates recommended to avoid fluid overload; monitor renal function and electrolyte balance.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
None
None
Use with caution in patients with congestive heart failure, renal impairment, or hyperglycemia,Monitor serum glucose, electrolytes, and fluid status,Risk of hyperglycemia and hyperosmolar syndrome in patients with diabetes mellitus or stress-induced insulin resistance,Not for use in patients with intracranial or intraspinal hemorrhage or in patients who are comatose with hyperglycemia
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hyperglycemia,Hypersensitivity to any component,Severe electrolyte abnormalities (e.g., hypernatremia),Patients with known allergies to corn or corn products (dextrose derived from corn)
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
Avoid excessive intake of high-sodium foods such as processed snacks, canned soups, and fast foods to prevent exacerbation of sodium overload. No specific food interactions with dextrose; however, diabetic patients should monitor carbohydrate intake and adjust insulin accordingly. Alcohol may impair glucose metabolism and enhance hypoglycemia risk; avoid or limit consumption.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
No known teratogenic risk. Dextrose and sodium chloride are physiologic substances. In trimester 1, no increased risk of major malformations. In trimesters 2 and 3, use is safe when indicated for maternal hydration or electrolyte balance; avoid excessive dextrose causing maternal hyperglycemia which can lead to fetal hyperinsulinism and neonatal hypoglycemia.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Excreted into breast milk in small amounts; M/P ratio not clinically relevant. Dextrose and sodium chloride are normal milk components. Considered compatible with breastfeeding; monitor infant for signs of electrolyte imbalance if high doses administered to mother.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
No dose adjustment required for dextrose 5% and sodium chloride 0.45% in pregnancy. However, pregnant women have increased plasma volume; consider monitoring for fluid overload in conditions like preeclampsia. Insulin resistance may require glucose monitoring if large volumes are infused.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
This isotonic solution (D5 0.45% Na Cl) provides 170 kcal/L as dextrose and 77 m Eq/L sodium, 77 m Eq/L chloride. Use cautiously in patients with hyponatremia or sodium retention (heart failure, cirrhosis, renal impairment). Monitor serum glucose in diabetic patients; may cause hyperglycemia. Not suitable for resuscitation due to low sodium content. Avoid in patients with known allergy to corn-derived dextrose.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
Report any shortness of breath, swelling in legs, or rapid weight gain, as these may indicate fluid overload.,Inform your healthcare provider if you have diabetes, as this solution contains sugar and may affect blood glucose levels.,Tell your doctor if you have a history of kidney problems, heart failure, or high blood pressure.,Do not consume extra salt or salty foods without consulting your doctor.,Notify your nurse immediately if you experience pain, redness, or swelling at the infusion site.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% AND SODIUM CHLORIDE 0.45% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% is a Electrolyte that works by Dextrose 5% provides a source of calories and hydration; sodium chloride 0.45% provides electrolytes and maintains osmotic balance. Dextrose is metabolized to carbon dioxide and water, yielding energy. Sodium chloride dissociates to maintain extracellular fluid volume and osmolality.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% AND SODIUM CHLORIDE 0.45% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% AND SODIUM CHLORIDE 0.45% is: Intravenous administration; typical adult dose is 1000-2000 m L over 24 hours, rate adjusted based on patient's fluid and electrolyte status. Maximum infusion rate is 1000 m L per hour.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% AND SODIUM CHLORIDE 0.45% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% AND SODIUM CHLORIDE 0.45% is classified as Category A/B. No known teratogenic risk. Dextrose and sodium chloride are physiologic substances. In trimester 1, no increased risk of major malformations. In trimesters 2 and 3, use is safe whe. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.